Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins

The rapidly growing recognition of the role of oncogenic ROS1 fusion proteins in the malignant transformation of multiple cancers, including lung adenocarcinoma, cholangiocarcinoma, and glioblastoma, is driving efforts to develop effective ROS1 inhibitors for use as molecularly targeted therapy. Usi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Davare, Monika A., Saborowski, Anna, Eide, Christopher A., Tognon, Cristina, Smith, Rebecca L., Elferich, Johannes, Agarwal, Anupriya, Tyner, Jeffrey W., Shinde, Ujwal P., Lowe, Scott W., Druker, Brian J.
Format: Artigo
Idioma:Inglês
Publicat: National Academy of Sciences 2013
Matèries:
Biological Sciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3845150/
https://ncbi.nlm.nih.gov/pubmed/24218589
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1319583110
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars